News
Antibody discovered by RQ Bio enters pivotal research phase
RQ Bio has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients – AZD3152 – has entered clinical trials less than 12 months after discovery. It follows AstraZeneca (AZ) receiving a licence for AZD3152 from RQ Bio in May 2022.